On Nov. 17, 2020, Celdara Medical announced that the NIH had awarded a two-year Small Business Innovation Research contract to fund the development of the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines.

This project build on the inventions of co-collaborators Dr. Sara Lustigman of New York Blood Center and Dr. Florian Krammer of the Icahn School of Medicine, Mount Sinai in New York.